Alibaba AI Strategy -2.1%: Wall Street Questions the AI Bet
Can Alibaba AI Strategy outrun geopolitics and weak consumer demand before Wall Street loses patience? Maik Kemper Editor in Chief The laws of the fields are very simple:…
Lucid Restructuring -3.1%: 18% Workforce Cut Stuns Street
Can Lucid Restructuring finally slow the cash burn, or is this just another reset for a still-unproven EV challenger? Maik Kemper Editor in Chief These are difficult decisions…
Nike Turnaround -3.8%: Wall Street Warns on Delayed Recovery
Can Nike Turnaround momentum survive another delay, or is Wall Street finally losing patience with the brand’s recovery story? Maik Kemper Editor in Chief What I didn’t realize…
Dell AI Infrastructure +2.6% as Rubin AI Factory Ignites
Can Dell AI Infrastructure turn a massive AI backlog into lasting margin power, or is this surge already pricing in perfection? Maik Kemper Editor in Chief This isn’t…
Alphabet DeepMind Departures: -6% Warning for AI Bulls
Can Alphabet’s massive AI backlog outweigh the shock of losing two of DeepMind’s most important researchers? Maik Kemper Editor in Chief We are compute constrained in the near…
Super Micro Computer AI Infrastructure Jumps 13.8% on AI
Can Super Micro Computer AI Infrastructure turn a one-day surge into a lasting lead in the AI data center race? Maik Kemper Editor in Chief Scientific discovery has…
Robinhood Convertible Notes: $2B Deal Boosts Flexibility
Why is Robinhood betting on a $2 billion convertible raise when its platform momentum already looks strong? Maik Kemper Editor in Chief Robinhood’s strong activity trends demonstrate continued…
Alphabet DeepMind Departures: -6.3% Warning for AI Bulls
Can Alphabet keep its AI edge as top DeepMind talent exits and Wall Street punishes the stock? Maik Kemper Editor in Chief We are compute constrained in the…
Broadcom Google AI Deal -4% as JPMorgan Backs TPU Path
If the Broadcom Google AI Deal is truly locked in through 2031, why is AVGO still sliding? Maik Kemper Editor in Chief Contrary to the recent noise… that…
AbbVie Acquisition +4.5%: AbbVie Bets Big on Apogee
Is AbbVie’s $10.9 billion Apogee deal a bold immunology masterstroke, or an expensive bet on future growth? Maik Kemper Editor in Chief The acquisition of Apogee further builds…